Back to today’s briefing

Story perspectives

Recursion and MIT Unveil AI Model Revolutionizing Drug Development

6/11/2025

37 5

Summary

Story summary

Recursion Pharmaceuticals collaborates with MIT to create Boltz-2, an AI model that predicts binding affinity 1000 times faster than traditional methods.
This breakthrough accelerates drug development and boosts Recursion's stock value.
The company competes with Moderna and Illumina while navigating regulatory approval challenges.
Upcoming investor conferences could influence stock performance and attract investor interest.

1 of 1

Story summary

Recursion Pharmaceuticals collaborates with MIT to create Boltz-2, an AI model that predicts binding affinity 1000 times faster than traditional methods.
This breakthrough accelerates drug development and boosts Recursion's stock value.
The company competes with Moderna and Illumina while navigating regulatory approval challenges.
Upcoming investor conferences could influence stock performance and attract investor interest.